{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-145634","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.363532+00:00","generated_at":"2026-06-25T21:42:09.180993+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atea Q1 net loss $42.1M; bemnifosbuvir misses primary endpoint but shows 71% hospitalization reduction","bullets":["Net loss of $42.1M ($0.51 per diluted share) vs net income of $30.7M in Q1 2021; revenue $0 vs $65.985M due to Roche termination.","Cash and equivalents $705.5M at March 31, 2022, down from $764.4M at Dec 31, 2021; $25M paid to Merck for ruzasvir license.","Bemnifosbuvir MORNINGSKY trial: primary endpoint (time to symptom alleviation) not met; 71% reduction in hospitalization (2.9% vs 10%, p=0.047, exploratory).","Phase 2 hospitalized COVID-19 study: 7.5% PRI on bemnifosbuvir vs 10% placebo; 0 deaths vs 3 deaths in placebo.","Initiated Phase 2 DEFEND-2 and human challenge trial for AT-752 in dengue; results expected 4Q22 and late 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-145634","json":"https://secwatch.observer/filing/0001193125-22-145634.json","markdown":"https://secwatch.observer/filing/0001193125-22-145634.md","text":"https://secwatch.observer/filing/0001193125-22-145634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522145634/0001193125-22-145634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522145634/d259165d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:42:09.180993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}